| AI Transforming the Modern Industrial Paradigm… Leading Companies Gain Attention with Industry-Specific Innovative Services
| The Future of the Global BioㆍPharmaceutical Business: JNPMEDI Supports the Industry with Its AI-Powered Solutions
Artificial Intelligence (AI) has become a cornerstone of modern industrial innovation. According to the global market research firm IDC (International Data Corporation), the generative AI market is projected to grow from $14.9 billion in 2023 to $151.1 billion by 2027—a remarkable 2.7-fold increase. With an astonishing compound annual growth rate (CAGR) of 86.1%, the market’s expansion is accelerating at an unprecedented pace.
Driving this rapid growth is not only the advancement of AI technology but also the strategic efforts of companies seeking to harness its full potential.
As the AI market expands, its applications are evolving beyond simple automation into industry-specific, cutting-edge solutions. From healthcare and finance to hospitality and beyond, AI-powered specialized services are emerging, enabling companies to differentiate themselves in an increasingly competitive landscape. This transformation is empowering businesses to respond more effectively to customer demands, creating new opportunities for innovation while strengthening their market position.
■ Pioneering the Digitalization of Clinical Trials: JNPMEDI Delivers Professional Services Across the BioㆍPharmaceutical Industry
JNPMEDI, emerging as a key global partner in the bio-pharma business beyond Korea, has continuously enhanced its services and technological capabilities to respond to the digital transformation (DX) of healthcare, centered around big data and AI.
Founded in 2020, JNPMEDI, a medical data platform company, has strengthened the capabilities of its AI-powered clinical operations and data management solution, ‘Maven Clinical Cloud.’ This solution is now being applied across various medical fields. Moving beyond decentralized clinical trials (DCT), JNPMEDI has successfully diversified its business strategies, product development, clinical research, regulatory affairs, and licensing out. It provides on-demand services at every stage of the pharmaceutical, biotech, and medical device industries.
Last year, JNPMEDI launched an organization focused on maximizing AI capabilities to accelerate digital innovation within the industry. The AI Research and Development (R&D) Task Force (TF), under the CTO's department, is composed of professionals in data platforms and AI development. It plays a central role in designing AI-based decision-making and automation processes. The team is currently involved in several projects, including the development of AI solutions for cancer diagnosis and AI product research for Maven Clinical Cloud.
The AI R&D TF is not only working to increase the efficiency of Maven Clinical Cloud-based solutions but also enhancing operational management capabilities to identify and mitigate risks that may arise during clinical trials and the commercialization processes of pharmaceuticals and medical devices. Additionally, the team is working on establishing effective systems for accumulating and analyzing clinical data, and is setting up and executing a long-term master plan to utilize AI technologies in various fields.
Moreover, JNPMEDI has partnered with Amazon Web Services (AWS), the global leader in cloud computing, to provide pharmaceutical and biotech companies with a more secure cloud environment for research and clinical trials.
Medical professionals traditionally map symptoms and medical observations, recorded in colloquial terms during clinical trials and research, to medical dictionary terms manually through medical coding. This mapping process is time-consuming and prone to errors, creating challenges in clinical trials. To address this, JNPMEDI developed "Maven Coder Express," a next-generation medical coder using AWS's generative AI platform, Amazon Bedrock, in August last year.
Maven Coder Express utilizes large language models (LLM) to suggest the conversion of narrative input by clinical researchers into standardized medical terminology suitable for data analysis. This process reduces the work time by up to 80%, maximizes coding accuracy, and improves data quality and consistency. Supporting 13 languages, including Korean, English, German, Japanese, and Chinese, it allows global medical professionals and researchers to use the tool without language barriers. Maven Coder Express also earned the Certified MedDRA Coder (CMC) certification, officially recognizing the high accuracy and consistency of its medical data coding results.
In addition, JNPMEDI is accelerating the digital transformation of clinical trials and AI innovation through collaborations with various companies and institutions. In October last year, JNPMEDI signed a memorandum of understanding with the Research Institute for Dementia, RID to develop AI-based clinical solutions. By integrating its clinical operation experience and AI development expertise into the group’s clinical trial preparation cohort, JNPMEDI is working on developing a high-speed digital clinical validation and regulatory platform. This will enable the rapid and accurate selection of suitable clinical trial participants, predict potential dropouts in advance, and enhance patient management systems, maximizing the success rate of clinical trials.
| AI Transforming the Modern Industrial Paradigm… Leading Companies Gain Attention with Industry-Specific Innovative Services
| The Future of the Global BioㆍPharmaceutical Business: JNPMEDI Supports the Industry with Its AI-Powered Solutions
Artificial Intelligence (AI) has become a cornerstone of modern industrial innovation. According to the global market research firm IDC (International Data Corporation), the generative AI market is projected to grow from $14.9 billion in 2023 to $151.1 billion by 2027—a remarkable 2.7-fold increase. With an astonishing compound annual growth rate (CAGR) of 86.1%, the market’s expansion is accelerating at an unprecedented pace.
Driving this rapid growth is not only the advancement of AI technology but also the strategic efforts of companies seeking to harness its full potential.
As the AI market expands, its applications are evolving beyond simple automation into industry-specific, cutting-edge solutions. From healthcare and finance to hospitality and beyond, AI-powered specialized services are emerging, enabling companies to differentiate themselves in an increasingly competitive landscape. This transformation is empowering businesses to respond more effectively to customer demands, creating new opportunities for innovation while strengthening their market position.
■ Pioneering the Digitalization of Clinical Trials: JNPMEDI Delivers Professional Services Across the BioㆍPharmaceutical Industry
JNPMEDI, emerging as a key global partner in the bio-pharma business beyond Korea, has continuously enhanced its services and technological capabilities to respond to the digital transformation (DX) of healthcare, centered around big data and AI.
Founded in 2020, JNPMEDI, a medical data platform company, has strengthened the capabilities of its AI-powered clinical operations and data management solution, ‘Maven Clinical Cloud.’ This solution is now being applied across various medical fields. Moving beyond decentralized clinical trials (DCT), JNPMEDI has successfully diversified its business strategies, product development, clinical research, regulatory affairs, and licensing out. It provides on-demand services at every stage of the pharmaceutical, biotech, and medical device industries.
Last year, JNPMEDI launched an organization focused on maximizing AI capabilities to accelerate digital innovation within the industry. The AI Research and Development (R&D) Task Force (TF), under the CTO's department, is composed of professionals in data platforms and AI development. It plays a central role in designing AI-based decision-making and automation processes. The team is currently involved in several projects, including the development of AI solutions for cancer diagnosis and AI product research for Maven Clinical Cloud.
The AI R&D TF is not only working to increase the efficiency of Maven Clinical Cloud-based solutions but also enhancing operational management capabilities to identify and mitigate risks that may arise during clinical trials and the commercialization processes of pharmaceuticals and medical devices. Additionally, the team is working on establishing effective systems for accumulating and analyzing clinical data, and is setting up and executing a long-term master plan to utilize AI technologies in various fields.
Moreover, JNPMEDI has partnered with Amazon Web Services (AWS), the global leader in cloud computing, to provide pharmaceutical and biotech companies with a more secure cloud environment for research and clinical trials.
Medical professionals traditionally map symptoms and medical observations, recorded in colloquial terms during clinical trials and research, to medical dictionary terms manually through medical coding. This mapping process is time-consuming and prone to errors, creating challenges in clinical trials. To address this, JNPMEDI developed "Maven Coder Express," a next-generation medical coder using AWS's generative AI platform, Amazon Bedrock, in August last year.
Maven Coder Express utilizes large language models (LLM) to suggest the conversion of narrative input by clinical researchers into standardized medical terminology suitable for data analysis. This process reduces the work time by up to 80%, maximizes coding accuracy, and improves data quality and consistency. Supporting 13 languages, including Korean, English, German, Japanese, and Chinese, it allows global medical professionals and researchers to use the tool without language barriers. Maven Coder Express also earned the Certified MedDRA Coder (CMC) certification, officially recognizing the high accuracy and consistency of its medical data coding results.
In addition, JNPMEDI is accelerating the digital transformation of clinical trials and AI innovation through collaborations with various companies and institutions. In October last year, JNPMEDI signed a memorandum of understanding with the Research Institute for Dementia, RID to develop AI-based clinical solutions. By integrating its clinical operation experience and AI development expertise into the group’s clinical trial preparation cohort, JNPMEDI is working on developing a high-speed digital clinical validation and regulatory platform. This will enable the rapid and accurate selection of suitable clinical trial participants, predict potential dropouts in advance, and enhance patient management systems, maximizing the success rate of clinical trials.